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changes in appearance can adversely impact many aspects 
of health-related quality of life, including social interactions 
(2). Individuals with visible differences have reported dif-
ficulty navigating social situations because of issues such as 
staring, invasive questions, and rude comments (2-4). Such 
experiences may result in anxiety that is specifically related 
to fears about interacting and mingling with others; this has 
been termed social interaction anxiety (5).
The Social Interaction Anxiety Scale (SIAS) is a self-report 
measure specifically developed to measure social interaction 
anxiety (5). The SIAS is a unidimensional measure that has 
demonstrated excellent internal consistency reliability in both 
clinical (e.g., social anxiety, agoraphobia) and non-clinical 
(e.g., undergraduate) samples (α = 0.88-0.93) (5, 6) as well as 
sensitivity to change following interventions targeting  social 
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Introduction
The study of body image and associated constructs in a 
medical context has been called “one of the new frontiers” of 
body image research (p. 8) (1). Medical conditions that cause 
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anxiety (5, 7). Peters and colleagues (8) developed a one-
factor six-item short form of the SIAS, the SIAS-6. The SIAS-6 
has demonstrated strong correlations with the original SIAS 
(ranging from r = 0.88 to r = 0.92) and related constructs (e.g., 
social appearance anxiety) in clinical and non-clinical samples 
(8). However, the factor structure and internal consistency re-
liability of the SIAS-6 have not been examined in the context 
of disfigurement from medical illness or injury.
Systemic sclerosis (SSc, or scleroderma) is a chronic and 
progressive autoimmune connective tissue disease with 
no known cure that is associated with marked appearance 
changes in visible and socially relevant areas of the body, in-
cluding the hands and face (9-12). The disease’s most com-
mon visible characteristic is skin thickening. Although SSc can 
have a heterogeneous presentation, it is typically divided into 
limited and diffuse subtypes, based on where skin thicken-
ing occurs. In limited disease, skin thickening is typically only 
present in the hands, arms, and face; in diffuse disease, skin 
involvement also includes the truncal region (13, 14). Appear-
ance concerns are common in patients with both subtypes 
and can include a pinched appearance to the nose and eyes; 
contractures and amputations of the digits; loss of volume 
and flexibility of the lips; hypo- and hyper-pigmentation; and 
telangiectasias (11). Disease-related changes to appearance 
in SSc have been associated with appearance dissatisfac-
tion and social discomfort (9, 15, 16). In a qualitative study, 
Joachim and Acorn (17) described SSc patients’ concerns 
about calling attention to themselves in public and fears of 
stigmatization based on their appearance. For patients with 
SSc who struggle with unwanted appearance changes, there 
has been a call for increased research in order to inform as-
sessments and interventions for body image distress and its 
social impacts (12, 18). To date, however, social interaction 
anxiety has not been studied in SSc.
The present study examines the reliability (internal consis-
tency) and validity (structural and convergent) of the SIAS-6 
in patients with SSc, and compares these psychometric prop-
erties across limited and diffuse subtypes of the disease. We 
hypothesized that a one-factor structure would provide the 
best fit for the data for both SSc disease subtypes and that in-
ternal consistency reliability would be high (Cronbach’s alpha 
≥0.80). In previous research with the SIAS-6, moderate-to-
large relationships have been demonstrated with measures of 
social anxiety (r = 0.54), fear of negative evaluation (r = 0.42), 
and depression (r = 0.48) (8) and a moderate relationship be-
tween the full-length SIAS and a measure of appearance satis-
faction (r = -0.46) (19). Effect sizes for correlations have been 
described as small (|r|≤0.3), moderate (0.3<|r|<0.5), or large 
(|r|≥0.5) (20). It was hypothesized that higher SIAS-6 scores 
would have moderate-to-large associations with measures of 
social appearance anxiety, social discomfort, and fear of nega-
tive evaluation, and smaller associations with measures of ap-
pearance dissatisfaction and symptoms of depression.
Patients and methods
Participants and procedures
The present study is a cross-sectional analysis of baseline 
data of patients enrolled in the Scleroderma Patient-centered 
Intervention Network (SPIN) Cohort who completed the SIAS-
6. To be eligible for the SPIN Cohort, patients must have a 
confirmed diagnosis of SSc according to the 2013 American 
College of Rheumatology/European League Against Rheuma-
tism classification criteria (21), be aged ≥18, be able to give 
informed consent, be fluent in English or French, and have 
the ability to respond to questionnaires via the Internet. The 
SPIN sample is a convenience sample. Eligible patients are in-
vited by the attending physician or a supervised nurse coordi-
nator to participate in the SPIN Cohort, and written informed 
consent is obtained. The local SPIN physician or supervised 
nurse coordinator then completes a medical data form that 
is submitted online to initiate patient registration in the SPIN 
Cohort. After completion of online registration, an automat-
ed welcoming email is sent to participants with instructions 
on how to activate their SPIN online account and how to com-
plete the SPIN Cohort patient measures online. SPIN Cohort 
patients should complete outcome measures via the Internet 
upon enrollment and subsequently every three months. The 
SPIN Cohort study was approved by the Research Ethics Com-
mittee of the Jewish General Hospital, Montreal, Canada and 
by the Institutional Reviews Boards of each participating cen-
ter. Patients included in the present study were enrolled at 27 
SPIN centers in Canada, the USA, and the UK. Only data from 
the baseline assessments of English-speaking participants 
completed from April 2014 to February 2017 were analyzed.
Measures
SIAS-6 (8). The SIAS-6 is a six-item measure of anxiety as-
sociated with initiating and maintaining social interactions, 
which was developed from the 20-item SIAS (5). Response 
options range from 0 (not at all characteristic or true of me) 
to 4 (extremely characteristic or true of me). A total score is 
computed by summing all items, with scores ranging from 0 
to 24. Higher scores correspond to greater social interaction 
anxiety.
Social Appearance Anxiety Scale (SAAS) (19). The SAAS is a 
16-item measure of anxiety about being negatively evaluated 
by others because of one’s appearance. Items are scored on 
a five-point scale ranging from 1 (not at all) to 5 (extremely). 
Total scores range from 16 to 80, with higher scores indicating 
greater anxiety. A psychometric analysis supported the struc-
tural validity, convergent validity, and internal consistency 
of the SAAS in SSc (16). Internal consistency reliability in the 
present sample was excellent (α = 0.96).
Brief Fear of Negative Evaluation Scale – Revised (BFNE-II) 
(22). The BFNE-II assesses fears of being negatively evaluated 
by others. Items are scored on a five-point scale ranging from 
1 (not at all characteristic of me) to 5 (extremely characteris-
tic of me). Total scores range from 12 to 60, with higher scores 
indicating greater fear of negative evaluation. The BFNE-II has 
demonstrated strong internal consistency in non-SSc popula-
tions (22, 23). Internal consistency reliability in the present 
sample was excellent (α = 0.98).
Brief Satisfaction with Appearance Scale (Brief-SWAP) 
(15). The Brief-SWAP is a six-item measure of body image 
dissatisfaction, adapted from the full SWAP (24) with the fol-
lowing two subscales: Dissatisfaction with Appearance and 
Social Discomfort. Respondents report appearance-related 
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concerns on a seven-point scale ranging from 0 (strongly dis-
agree) to 6 (strongly agree). Subscale scores range from 0 to 
18, with higher scores indicating greater appearance-related 
discomfort and dissatisfaction. The structural validity, conver-
gent validity, and internal consistency of the measure have 
been supported with SSc patients (16, 25). Internal consisten-
cy reliability in the present sample for the Dissatisfaction with 
Appearance and Social Discomfort subscales was excellent 
(α = 0.83 and α = 0.88, respectively).
Patient Health Questionnaire (PHQ-8) (26). The PHQ-8 
items measure depressive symptoms over the last two weeks 
on a four-point scale, ranging from 0 (not at all) to 3 (nearly 
every day). A total score is obtained by summing item scores, 
with higher scores indicating more depressive symptoms. The 
PHQ-8 performs equivalently to the PHQ-9 (27), which is a 
valid measure of depressive symptoms in patients with SSc 
(28). Internal consistency reliability in the present sample was 
excellent (α = 0.89).
Sociodemographic and Medical Variables. Patients self-
reported sociodemographic data. SPIN physicians reported 
medical information, including modified Rodnan skin scores 
(mRss) (29, 30) a measure of skin thickening with scores rang-
ing from 0 to 51, with higher scores reflecting greater thicken-
ing and disease involvement, and disease subtype.
Data analysis
Descriptive statistics for sociodemographic and medical 
variables were calculated for the sample with SPSS, version 
22.0. Confirmatory factor analysis (CFA) was conducted to 
confirm the single-factor structure of the SIAS-6 using  Mplus 
version 7.12. MLR estimation, which provides maximum 
likelihood parameter estimates with standard errors and a 
chi-square statistic that is robust to non-normality, and non-
independence of observations, was used in the present anal-
ysis. Modification indices were also requested to examine 
whether freeing parameters would improve model fit. After 
establishing structural validity, multiple group CFA was used, 
as described by Dimitrov (31), to evaluate the comparability 
of the factor structures, also referred to as measurement in-
variance, of the SIAS-6 for patients with limited and diffuse 
SSc via the following, iteratively restrictive models: (i) con-
figural invariance; (ii) metric invariance; and (iii) scalar invari-
ance. Briefly, this approach [recommended by Vandenberg 
and Lance (32)] first examines the baseline fit of the mea-
surement model in both groups by constraining the number 
of factors and the items contributing to each factor to estab-
lish configural invariance, which demonstrates that the same 
factor structure exists for both groups. Next, a more restric-
tive model is run, such that the loading of each item onto the 
factor is constrained to equivalence between the groups to 
establish metric invariance, which suggests that the same fac-
tor loadings exist for both groups. If both the previous models 
demonstrate good fit, a third, even more restrictive, model is 
run to establish scalar invariance, to demonstrate that, in ad-
dition to factor loadings, the same item intercepts also exist 
for both groups.
Overall model fit was determined using the recommenda-
tions of Bentler (33). Three indicators of model fit were utilized, 
including: (a) the root-mean-square error of approximation 
(RMSEA) (34), with values <0.08 indicating acceptable fit and 
values <0.05 indicating good fit; (b) the standardized root-
mean residual (SRMR) (35), an index of overall model fit with 
values <0.08 indicating acceptable fit and values <0.05 indicat-
ing good fit; and (c) the comparative fit index (CFI) (33), with 
values >0.95 indicating good model fit and values >0.90 indicat-
ing acceptable model fit. The Satorra and Bentler (36) scaling 
factors were used for the chi-square value, given statistically 
significant multivariate skewness and kurtosis in the present 
data (all p<0.05). Because the likelihood-ratio chi-square (χ2) 
is influenced by sample size, it was not the sole indicator of 
model fit (37). Per previously established criteria (37, 38) the 
Satorra-Bentler Scaled chi-square (S-Bχ2) (39) difference test 
and the CFI values were used to compare the increasingly re-
strictive multiple-group CFA models such that a non-statisti-
cally significant (p>0.05) change in S-Bχ2 or a change in CFI of 
≤0.01 indicated no difference between the nested models; in 
other words, adding more restrictions would not significantly 
compromise good model fit (40).
Internal consistency reliability for the SIAS-6 items was 
calculated using Cronbach’s coefficient alpha. Convergent va-
lidity was examined via Spearman correlations of the SIAS-6 
with the SAAS, BFNE-II, Brief-SWAP, and PHQ-8. The afore-
mentioned hypotheses regarding the direction and magni-
tude of the relationships were established a priori, based 
on prior research with the SIAS-6. Scores between the two 
groups were compared using Independent Samples t-tests.
A minimum sample size estimation for a one-factor CFA 
with six items, assuming factor loadings between 0.50 and 
0.80, is between 60 and 190 participants (41). Regarding 
minimum sample size for the proposed correlation analyses, 
a correlation that can be assessed with 95% confidence and 
precision of 0.10 would require a minimum sample size of 
403 for a small correlation (r = 0.30) and at least 275 for a 
large correlation (r = 0.50) (42). Thus, the present sample size 
exceeded the minimum sample size requirements.
Results
Sample statistics are reported in Table I. Three participants 
who left the second item of the SIAS-6 blank were removed 
from the analysis. Participants (n = 802) were predominantly 
female (87%), married (74%), and had a mean age of 55.5 
years (SD = 12.0).
Confirmatory factor analysis
CFA confirmed the one-factor model of the SIAS-6 [S-Bχ2 
(9) = 30.2, p<0.01; CFI = 0.99, RMSEA = 0.05, SRMR = 0.02]. 
Individual item factor loadings are provided in Table II. The 
modification indices were examined; however, no parameters 
were freed, given that the one-factor model fit well without 
modification.
Multiple-group confirmatory factor analysis models
The one-factor model fit the data well for limited and dif-
fuse disease groups (see Tab. II). Additionally, the factor load-
ings were statistically significant for all items in both groups 
(see Tab. III). The metric invariance model fit the data well 
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 descriptively (CFI = 1.00, RMSEA: 0.00, SRMR: 0.04; see Tab. II). 
Comparing the less restrictive configural invariance model to 
the more constrained metric invariance model, the results 
suggested that the metric model did not worsen fit statistical-
ly (ΔS-Bχ2 = 5.84 df = 5, p = 0.32) or descriptively (ΔCFI≤0.01). 
The scalar model also demonstrated good fit (CFI = 1.00, RM-
SEA: 0.00, SRMR: 0.04; see Tab. II). When compared to the less 
restrictive metric invariance model, fit was not compromised 
(ΔS-Bχ2 = 5.71 df = 5, p = 0.33, ΔCFI≤0.01).
TABLE I -  Sociodemographic, disease, and psychosocial variables 
for sample (n = 802)
Sociodemographic variables
 Age (mean, SD) 55.55 (12.0)a
 Female (n, %) 697 (86.9)
 White (n, %) 686 (85.6)
 Years of formal education (mean, SD) 15.40 (3.2)
 Employed full or part-time (n, %) 326 (64.4)b
 Married or living as married (n, %) 595 (74.2)
Disease variables
 Diffuse scleroderma (n, %) 350 (43.6)
  Disease duration (time since first non-Raynaud’s 
symptom) in years (mean, SD)
11.61 (8.8)c
 Modified Rodnan skin score (mean, SD) 8.22 (9.0)d
Psychosocial measures (mean, SD)e
 SIAS-6 2.43 (3.8)
  Limited 2.06 (3.1)
  Diffuse 2.91 (4.5)
 Brief-SWAP-dissatisfaction with Appearance 9.28 (5.21)f
 Brief-SWAP-social discomfort 5.34 (5.22)g
 PHQ-8 6.03 (5.4)h
 SAAS 28.09 (13.0)i
 BFNE-II 24.80 (12.2)j
Due to missing values: an = 799; bn = 801; cn = 744; dn = 639; eSAAS = Social 
Appearance Anxiety Scale; SWAP = Satisfaction with Appearance Scale; PHQ-8 
= Patient Health Questionnaire-8; SIAS-6 = Social Interaction Anxiety Scale; 
BFNE-II = Brief Fear of Negative Evaluation Scale-Revised.
Due to missing values; fn = 795; gn = 794; hn = 792; in = 794; jn = 7.
TABLE II -  Fit statistics for configural invariance, metric invariance, and scalar invariance models of the Social Interaction Anxiety Scale-6 
(SIAS-6)
Model S-Bχ2 p CFIa SRMRb RMSEAb Reference model # DS-Bχ2 Ddf Dp DCFI
1. Configural
 Limited 8.77 0.46 1.00 0.02 0.00
 Diffuse 7.34 0.60 1.00 0.02 0.09
2. Metric 21.98 0.52 1.00 0.04 0.00 1 5.84 5 0.32 <0.01
3. Scalar 27.17 0.51 1.00 0.04 0.00 2 5.71 5 0.33 <0.01
a Plausible fit ≥0.90, good fit >0.95.
b Plausible fit ≤0.08, good fit ≤0.05.
CFI = robust comparative fit index; RMSEA = root-mean-square error of approximation; SRMR = standardized root-mean-square residual.
Descriptive statistics for the SIAS-6
The total score for the SIAS-6 in the full sample was 2.43 
(SD = 3.8; range: 0-24). The limited group mean was 2.06 
(SD = 3.1; range 0-18), whereas the diffuse group mean was 
2.91 (SD = 4.5; range 0-24). Internal consistency reliability 
was excellent for the total sample (α = 0.89) as well as for lim-
ited (α = 0.86) and diffuse subgroups (α = 0.90). Comparing 
group means, the scores were significantly different between 
groups (p<0.01; 95% CI: -1.39, -0.29). Thus, patients with dif-
fuse disease reported significantly greater social interaction 
anxiety than patients with limited disease.
Convergent validity
Consistent with the relationships hypothesized, SIAS-6 
scores had positive, large correlations with measures of social 
appearance anxiety (rs = 0.50, p<0.01) and fear of negative 
evaluation (rs = 0.60, p<0.01), a moderate, positive correlation 
with a measure of social discomfort (rs = 0.43, p<0.01), and 
a small, positive correlation with appearance dissatisfaction 
(rs = 0.23, p<0.01). Contrary to the authors’ expectations, 
there was a moderate rather than small correlation with 
symptoms of depression (rs = .41, p<0.01; see Tab. IV).
Discussion
The results of the present study suggest that the SIAS-6 
is a reliable and valid one-factor measure of social interac-
tion anxiety for patients with SSc. Moreover, the multi-group 
confirmatory factor analysis provided support for the scalar 
invariance model, suggesting that scores can be meaning-
fully compared between limited and diffuse disease groups 
(40, 43). Internal consistency reliability was strong, and con-
vergent validity was supported via significant correlations 
with relevant measures in the expected magnitudes and di-
rections, except for the correlation with depressive symptom-
atology via the PHQ-8, which was larger than expected.
Given a possible range for total scores of 0 to 24, average 
scores for SSc patients in the range of 2 to 3 represent a low 
level of social interaction anxiety. In previous research, scores 
have been consistently higher among individuals receiving 
treatment for social anxiety [e.g., mean = 13.2; SD = 4.9 (8); 
Validation of the Social Interaction Anxiety Scale in scleroderma102 
mean = 12.52; SD = 5.14 (44)] and among sexual minorities 
[e.g., mean = 4.7; SD  = 4.8 (45)]. However, scores from com-
munity-dwelling adults without clinically significant anxiety 
symptoms have been lower [e.g., mean = 1.5; SD  = 2.25 (44)], 
and similar to the scores found for SSc patients in the present 
study. To the authors’ knowledge, the SIAS-6 has not been used 
previously in any samples with medical disfigurement, though 
a study using the full-length SIAS in a sample of patients with 
spasmodic torticollis (ST), a neurological condition causing in-
voluntary neck contortions, found that ST patients had signifi-
cantly higher SIAS scores as compared to non-affected controls 
(46). The SIAS-6 has not yet been used in other rheumatologic 
conditions, limiting comparisons to other diseases. Given the 
good psychometric properties of the SIAS-6 in SSc, researchers 
interested in interactional anxiety among patients with other 
conditions, may consider including the SIAS-6 as a measure of 
social interaction anxiety.
The results of the present study should be interpreted in the 
context of limitations. The SPIN Cohort is a convenience sam-
ple of patients receiving treatment at SPIN recruiting centers 
who complete study questionnaires online, potentially limiting 
generalizability. Additionally, the cross-sectional design of the 
present study precluded evaluations of sensitivity to change or 
test-retest reliability. A potential limitation of the measure is 
that all six items are positively worded. Most of the psycho-
metric literature examining the role of negatively worded and 
reverse-scored items in minimizing response-bias has identi-
fied that negatively worded items can contribute to problems 
with internal consistency and factor structure (47). Barnette 
(47) examined the role of stem direction, item response direc-
tion, and Cronbach’s alpha and identified that the best psycho-
metric properties were achieved for measures with all directly 
worded stems and a mixture of directionality for response op-
tions. Future researchers who conduct psychometric work on 
this measure may consider testing the use of such alternative 
response options. Additionally, this study identified a dispar-
ity in scores such that patients with diffuse disease had higher 
scores than patients with limited disease. The present study 
was not powered to examine the role of various disease sub-
type-related variables (e.g., skin score, lung disease) or other 
medical characteristics (e.g., disease duration) in SIAS-6 scores. 
It may be interesting to identify the disease subtype-related 
variables associated with SIAS-6 scores in future research as 
the study sample grows. Additionally, exploring disease charac-
teristics that can impact body image (e.g., facial involvement, 
location of telangiectasias, hand involvement) or participant 
characteristics (e.g., race/ethnicity, gender, marital status) may 
also be an interesting aim in future research that can inform in-
terventions for social problems. Examining correlates of group 
membership in quartiles or identifying cut-off scores may be 
warranted in future research endeavors. Finally, it is conceiv-
able that a disease-specific measure of social interaction anxi-
ety that captures challenges of social interactions unique to SSc 
populations (e.g., fears about shaking hands) may better assess 
social interaction anxiety in individuals with SSc. Despite these 
limitations, the results of the present study provide important 
psychometric support for the use of the SIAS-6 to measure so-
cial interaction anxiety among patients with SSc.
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